Publications by authors named "Stergios J Moschos"

49Publications

Chemotherapy Following PD-1 Inhibitor Blockade in Patients with Unresectable Stage III/Stage IV Metastatic Melanoma: A Single Academic Institution Experience.

Oncology 2020 3;98(3):174-178. Epub 2019 Dec 3.

Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000504578DOI Listing
March 2020

Prognostic value of B cells in cutaneous melanoma.

Genome Med 2019 05 28;11(1):36. Epub 2019 May 28.

Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13073-019-0647-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540526PMC
May 2019

Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis.

J Invest Dermatol 2019 06 6;139(6):1349-1361. Epub 2018 Dec 6.

Department of Dermatology, School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA; Lineberger Comprehensive Cancer Center (LCCC), University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2018.11.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535139PMC
June 2019

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

N Engl J Med 2018 Aug;379(8):722-730

From the University of Texas M.D. Anderson Cancer Center, Houston (H.A.T.); Moffitt Cancer Center and Research Institute, Tampa, FL (P.A.F., N.I.K.); University of California-San Francisco, San Francisco (A. Algazi), the Angeles Clinic and Research Institute, Los Angeles (O.H.), Stanford University Hospital, Palo Alto (R.P.T.), and the Department of Medical Oncology, City of Hope, Duarte (K.M.) - all in California; Dana-Farber Cancer Institute, Boston (F.S.H., D.A.R.); University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill (S.J.M.); University of Colorado Comprehensive Cancer Center, Aurora (K.L.); University of Michigan, Ann Arbor (C.D.L.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (M.A.P.), Roswell Park Cancer Institute, Buffalo (M.S.E., I.P.), and New York University, Lake Success (A.C.P.) - all in New York; Georgetown-Lombardi Comprehensive Cancer Center, Washington DC (M.B.A.); Winship Cancer Institute of Emory University, Atlanta (R.R.K.); University of Pittsburgh Medical Center, Pittsburgh (A.T.); Bristol-Myers Squibb, Princeton, NJ (J.J., A. Avila, S.D.); and Cleveland Clinic-Taussig Cancer Institute, Cleveland (A.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1805453DOI Listing
August 2018

Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma.

Melanoma Res 2017 08;27(4):342-350

aDepartment of Medicine, Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania bLudwig Institute for Cancer Research Ltd, New York, New York cDepartment of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000353DOI Listing
August 2017

The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy.

Anticancer Drugs 2017 07;28(6):669-675

aUNC Lineberger Comprehensive Cancer Center Departments of bRadiation Oncology cMedicine dNeurosurgery, University of North Carolina, Chapel Hill, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000497DOI Listing
July 2017

Use of Susceptibility-Weighted Imaging (SWI) in the Detection of Brain Hemorrhagic Metastases from Breast Cancer and Melanoma.

J Comput Assist Tomogr 2016 Sep-Oct;40(5):803-5

From the *Department of Radiology, New York University Medical Center, New York, NY; and †Division of Hematology and Oncology, Department of Medicine, UNC at Chapel Hill, Chapel Hill, NC; ‡Neuroradiology Section, Department of Radiology, The University of North Carolina School of Medicine, Chapel Hill, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RCT.0000000000000420DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027959PMC
January 2017

Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis.

Cancer Treat Rev 2016 Apr 2;45:30-7. Epub 2016 Mar 2.

UNC Lineberger Comprehensive Cancer Center, 170 Manning Drive, CB# 7305, Chapel Hill, NC 27599, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03057372160003
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2016.02.006DOI Listing
April 2016

Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.

J Biopharm Stat 2016 ;26(1):141-9

b Department of Medicine , The University of North Carolina at Chapel Hill , Chapel Hill , North Carolina , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10543406.2015.1092030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995106PMC
October 2016

Targeted therapies in melanoma.

Surg Oncol Clin N Am 2015 Apr 24;24(2):347-58. Epub 2015 Jan 24.

Division of Hematology/Oncology, Department of Medicine, East Carolina University, 600 Moye Boulevard, Brody 3E127, Greenville, NC 27834, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.soc.2014.12.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494792PMC
April 2015

DNA methylation profiles in primary cutaneous melanomas are associated with clinically significant pathologic features.

Pigment Cell Melanoma Res 2014 Nov 14;27(6):1097-105. Epub 2014 Jul 14.

Department of Dermatology, University of North Carolina, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12289DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211983PMC
November 2014

HIF1α and HIF2α independently activate SRC to promote melanoma metastases.

J Clin Invest 2013 May 8;123(5):2078-93. Epub 2013 Apr 8.

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7295, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI66715DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3635738PMC
May 2013

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.

J Clin Oncol 2012 Jan 19;30(3):322-8. Epub 2011 Dec 19.

University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center Cancer Pavilion, 5150 Centre Ave, Fifth Fl, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.37.5394DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422533PMC
January 2012

Functional analysis and molecular targeting of aurora kinases a and B in advanced melanoma.

Genes Cancer 2010 Sep;1(9):952-63

Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1947601910388936DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092253PMC
September 2010

The use of endostatin in the treatment of solid tumors.

Expert Opin Biol Ther 2009 May;9(5):641-8

Department of Biological Chemistry, National & Kapodistrian University of Athens Medical School, Athens, Greece.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1517/147125909028821
Publisher Site
http://dx.doi.org/10.1517/14712590902882118DOI Listing
May 2009

Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma?

Nat Clin Pract Oncol 2009 Feb 17;6(2):70-1. Epub 2008 Dec 17.

Department of Medicine, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/ncponc1297
Publisher Site
http://dx.doi.org/10.1038/ncponc1297DOI Listing
February 2009

Next generation of immunotherapy for melanoma.

J Clin Oncol 2008 Jul;26(20):3445-55

Hillman Cancer Center, Research Pavilion, Suite 1.32, 5117 Centre Ave, Pittsburgh, PA 15213-2584, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.14.6423DOI Listing
July 2008

Resolving "kinks" of chemotherapy in melanoma.

J Natl Cancer Inst 2008 Jun 10;100(12):833-5. Epub 2008 Jun 10.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djn189DOI Listing
June 2008

Focus on FOCIS: interleukin 2 treatment associated autoimmunity.

Clin Immunol 2008 May;127(2):123-9

University of Pittsburgh Federation of Clinical Immunologic Societies Center of Excellence, Pittsburgh, Pennsylvania 15213-1683, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clim.2008.02.011DOI Listing
May 2008

Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma.

Nat Clin Pract Oncol 2008 Jan 13;5(1):2-3. Epub 2007 Nov 13.

Department of Medicine, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncponc1004DOI Listing
January 2008

Integrins and cancer.

Oncology (Williston Park) 2007 Aug;21(9 Suppl 3):13-20

Department of Medicine, Division of Hematology/Oncology, Melanoma and Skin Cancer Program, University of Pittsburgh, Cancer Institute, USA.

View Article

Download full-text PDF

Source
August 2007

Role of SUMO/Ubc9 in DNA damage repair and tumorigenesis.

J Mol Histol 2006 Sep 7;37(5-7):309-19. Epub 2006 Jun 7.

Department of Medicine, Division of Hematology-Oncology, Hillman Cancer Research Pavilion, University of Pittsburgh Medical Center, 5117 Centre Avenue, Suite 1.32e, Pittsburgh, PA 15213, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10735-006-9030
Web Search
http://link.springer.com/10.1007/s10735-006-9030-0
Publisher Site
http://dx.doi.org/10.1007/s10735-006-9030-0DOI Listing
September 2006

Targeting Ubc9 for cancer therapy.

Expert Opin Ther Targets 2005 Dec;9(6):1203-16

Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University, PO Box 19626, Springfield, IL 62794, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/14728222.9.6.120
Publisher Site
http://dx.doi.org/10.1517/14728222.9.6.1203DOI Listing
December 2005

Melanoma.

Cancer Chemother Biol Response Modif 2005 ;22:563-90

The University of Pittsburgh, Cancer Institute, Melanoma Center, Pittsburgh, PA 15213-2584, USA.

View Article

Download full-text PDF

Source
October 2005

Recombinant methionyl human leptin administration activates signal transducer and activator of transcription 3 signaling in peripheral blood mononuclear cells in vivo and regulates soluble tumor necrosis factor-alpha receptor levels in humans with relative leptin deficiency.

J Clin Endocrinol Metab 2005 Mar 21;90(3):1625-31. Epub 2004 Dec 21.

D.Sc., Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, ST 816, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2004-1823DOI Listing
March 2005

Responsiveness to peripherally administered melanocortins in lean and obese mice.

Diabetes 2004 Jan;53(1):82-90

Department of Medicine, Division of Endocrinology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2337/diabetes.53.1.82DOI Listing
January 2004

The role of the IGF system in cancer: from basic to clinical studies and clinical applications.

Oncology 2002 ;63(4):317-32

Division of Endocrinology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000066230DOI Listing
December 2002